Glaucoma Awareness

The lower energy applications and slower sweep speeds offer marked IOP reductions in patients.

A team of investigators from the Yong Loo Lin School of Medicine at the National University of Singapore has found that there is a bidirectional association between chronic kidney disease and glaucoma.

The research is the result of a national collaboration led by investigators from the Centre for Eye Research Australia at the University of Melbourne and University of Tasmania and the Garvan Institute of Medical Research.

According to the company, no safety concerns with corneal endothelial health reported across all 3 trials, and the device delivered consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

Two grants will be available, each offering $150,000 to scientists focusing on glaucoma research who have already received their first independent federal National Institutes of Health (NIH) grant and are collecting new and novel data to apply for a second R01.

A complete understanding can help ophthalmologists get better results for their patients.

A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some of the previous challenges associated with cannabis use and may present a new potential therapeutic intervention in the treatment of glaucoma.

In advance of World Glaucoma Week March 6-12, a study of 3826 patients with glaucoma has found significantly higher odds of self-reported difficulty affording medication observed among non-Hispanic African American and Hispanic individuals compared with non-Hispanic White individuals.

The company’s new technology, which targets the eye’s conventional outflow pathway, is expected to have full commercial availability on April 1.

A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.

The glaucoma toolbox is expanding to include laser, drug delivery systems, and minimally invasive glaucoma surgery.

The company is revealing the 8-year follow up results of its novel Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery.

The GMOPC was established in February 2020 at an inaugural meeting in Los Angeles, California, as an investigator-initiated clinical research study, with Heidelberg Engineering as an industry partner.

According to the company, the protocol enhancement for the RETeval Device marks an important step in mitigating vision loss from glaucoma.

Mahmoud A. Khaimi, MD, developed a minimally invasive glaucoma surgery known as ab-interno canaloplasty as a treatment option between topical therapies and invasive surgery. The technique continues to prove its value.

The company’s IOPerfect combines artificial intelligence in a VR-like headset to allow tele-diagnosis and remote monitoring of glaucoma.

Alcon this week announced its plans to acquire glaucoma surgery device maker Ivantis Inc. in a $475 million deal.

Investigators in Australia are developing a new rapid screening test for glaucoma that could help advance early detection of the disease.

A coalition of vision groups held a briefing on Capitol Hill this week to educate legislators on increasing incidence of myopia and the associated cost burden.

To mark World Sight Day, Nanodropper Inc. has developed a pay-it-forward Nanodropper Adaptor program, allowing anyone to donate devices to a pool for distribution to patients in need.

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

New strategies are needed to rethink how we treat glaucoma to do more than just manage eye pressure—to actually restore vision by promoting the survival of retinal ganglion cells and their axons.

There’s no shortage of diet programs—Paleo, Mediterranean, intermittent fasting—all claiming to be the best option for a healthy life. Research has shown that poor lifestyle choices, including unhealthy diets, contribute to many diseases and that simply adhering to good nutrition can even prevent some health issues.

According to preliminary results, intranasally delivered ST266 is a safe treatment option.